Evidence map›Paper›PMID 25852820›Full record

ArticleClinical and translational medicine2015

Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: evaluation of plasma and lymphocyte expression.

Felipe M Cruz, Bruna A Munhoz, Beatriz Ca Alves, Flavia S Gehrke, Fernando LA Fonseca, Renata K Kuniyoshi, Daniel Cubero, Luke J Peppone, Auro Del Giglio

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02041364 unknown statusnot on this map

Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer: Evaluation of Plasma and Lymphocyte Expression.

TypeobservationalSponsorFaculdade de Medicina do ABCRan2013 to 2014Enrolled45ConditionsFatigue, Breast Cancer
NCT06662929 recruitingnot on this mapstarted 2023, after this paper: background citation

Arabic Patient-reported Outcome Measures During Radiotherapy for Head and Neck Cancer: a Validation Study

Typeobservational_patient_registrySponsorKing Saud UniversityRan2023 to 2025Enrolled125ConditionsHead and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx CancerArmsRadiation
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Trial
  5. Trial
  6. Trial
  7. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Multidimensional fatigue in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: incidence, severity, and risk factors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  12. Article
  13. Impact ofCurrent therapeutic research, clinical and experimental · 2020
    Article
  14. Article
  15. Chemotherapy-induced fatigue is associated with changes in gene expression in the peripheral blood mononuclear cell fraction of patients with locoregional breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Felipe M CruzDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Bruna A MunhozDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Beatriz Ca AlvesDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Flavia S GehrkeDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Fernando LA FonsecaDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Renata K KuniyoshiDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Daniel CuberoDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Luke J PepponeDepartment of Surgery, University of Rochester, Rochester, 14642 NY USA.
Auro Del GiglioDiscipline of Oncology and Hematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, 821, Santo André, 09060-650 SP Brazil.
Fundação do ABC · BRUniversity of Rochester · US

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Cancer Control Research Training Curriculum (R25T)R25CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C, MORROW, GARY R · 2004 to 2018
$6.7M
The University of Rochester Clinical and Translational Science InstituteKL2TR000095 · NCATS · UNIVERSITY OF ROCHESTER · PI BENNETT, NANCY M, KIEBURTZ, KARL D. · 2012 to 2015
$1.7M
Management of Cancer-Treatment-Induced Bone LossK07CA168911 · NCI · UNIVERSITY OF ROCHESTER · PI PEPPONE, LUKE JOSEPH · 2013 to 2017
$724k
NCI NIH HHS K07 CA168911NCI NIH HHS R25 CA102618NCI NIH HHS UG1 CA189961
6 · The paper itself

Abstract

backgroundFatigue is common in cancer patients receiving adjuvant chemotherapy. To further understand the mechanism of fatigue and search for potential biomarkers, we conducted this prospective study. Methods We enrolled breast cancer (BC) patients before their first adjuvant Adriamycin-based chemotherapy cycle. Patients responded to the brief fatigue inventory (BFI) and Chalder fatigue questionnaires and had their blood drawn for both plasma evaluation and evaluation of the peripheral mononuclear cell fraction (PMNCF) mRNA expression of various biomarkers. We evaluated FSH, LH, estradiol, DHEA, DHEAS, IL6, IL2, ILIRA, IL1β, CRP, Cortisol in the plasma and IL2, IL10, IL6, TGF-β, KLRC1, TNF, BTP, SNCA, SOD1, BLNK, PTGS2 and INF γ expression in the PMNCF.

results11 patients did not exhibit an increase in their BFI scores and served as controls, whereas 32 patients exhibited an increase in their BFI scores compared with the baseline scores. From the biomarkers we evaluated in the PMNCF, the only one significantly associated with fatigue was TGF-β (p = 0.0343), while there was a trend towards significance with KLRC1 (p = 0.0627). We observed no evidence of significant associations of any plasma biomarkers with the development of fatigue. However when we analyzed patients with more severe fatigue, plasma IL1-RA levels correlated directly with higher fatigue scores (p = 0.0136).

conclusionsWe conclude that fatigue induced by chemotherapy in BC patients is associated with changes in IL1-ra plasma levels and in TGF-β lymphocyte expression. Its mechanism may be different than that observed in long-term BC survivors or that induced by radiation therapy.

trial registrationNCT02041364 [ClinicalTrials.gov].

Indexed as

BiomarkersBreast CancerChemotherapyFatigueIL1-raTGF-β

Identifiers

PMID25852820
PMCPMC4385032
OpenAlexW2110867395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.